213 related articles for article (PubMed ID: 24171336)
1. Primary bone marrow B-cell non-Hodgkin's lymphoma successfully treated with R-CHOP.
Qian L; Zhang Z; Shen J; Liu Y
West Indian Med J; 2013 Jan; 62(1):89-91. PubMed ID: 24171336
[TBL] [Abstract][Full Text] [Related]
2. Intravascular large B-Cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen.
Jardin F; Callonnec F; Contentin N; Picquenot JM; Gueit I; Héron F; Bastard C; Tilly H
Clin Lymphoma; 2005 Jun; 6(1):46-9. PubMed ID: 15989707
[TBL] [Abstract][Full Text] [Related]
3. Primary bone marrow diffuse large B cell lymphoma: a case series and review.
Chang H; Hung YS; Lin TL; Wang PN; Kuo MC; Tang TC; Wu JH; Dunn P; Shih LY
Ann Hematol; 2011 Jul; 90(7):791-6. PubMed ID: 21181164
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
5. [Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia].
Sumi M; Ichikawa N; Shimizu I; Yotsumoto M; Ueno M; Kobayashi H
Rinsho Ketsueki; 2007 Jul; 48(7):571-5. PubMed ID: 17695307
[TBL] [Abstract][Full Text] [Related]
6. Rapid bone marrow dissemination after surgery in localized gastric diffuse large B-cell lymphoma: a case report.
Isoda A; Hatsumi N; Ogawa Y; Matsumoto M; Sawamura M
Int J Hematol; 2006 Dec; 84(5):471-2. PubMed ID: 17189234
[No Abstract] [Full Text] [Related]
7. Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature.
Bhagat P; Sachdeva MU; Sharma P; Naseem S; Ahluwalia J; Das R; Varma N; Law A; Malhotra P
Hematol Oncol; 2016 Mar; 34(1):42-8. PubMed ID: 25407700
[TBL] [Abstract][Full Text] [Related]
8. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
9. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M;
Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581
[TBL] [Abstract][Full Text] [Related]
10. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
[TBL] [Abstract][Full Text] [Related]
11. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T
J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035
[TBL] [Abstract][Full Text] [Related]
12. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
[TBL] [Abstract][Full Text] [Related]
15. [Primary diffuse large B-cell lymphoma of the uterine cervix successfully treated with rituximabplus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy-a case report].
Hashimoto A; Fujimi A; Kanisawa Y; Matsuno T; Okuda T; Minami S; Doi T; Ishikawa K; Uemura N; Jyomen Y; Tomaru U
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2589-92. PubMed ID: 24335377
[TBL] [Abstract][Full Text] [Related]
16. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
19. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]